证券代码：603259 证券简称：药明康德 公告编号：临 2025-068 无锡药明康德新药开发股份有限公司 第三届董事会第二十六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 无锡药明康德新药开发股份有限公司（以下简称"本公司"或"公司"）于 2025 年 10 月 10 日及 2025 年 10 月 23 日向本公司全体董事发出会议通知及会议 材料，全体董事一致同意豁免本次会议的通知期限要求，并以现场结合通讯表决 方式于 2025 年 10 月 24 日按期在公司会议室召开第三届董事会第二十六次会议。 本次董事会会议应出席董事 11 人，实际出席董事 11 人，会议由董事长 Ge L（i 李 革）主持。本次董事会符合《中华人民共和国公司法》和《无锡药明康德新药开 发股份有限公司章程》关于召开董事会会议的规定。 二、董事会会议审议情况 （一）审议通过《关于公司 2025 年第三季度报告的议案》 同意《无锡药明康德新药开发股份有限公司 2025 年第三季度报告》的相关 内容。 上述议案已 ...

Core Insights - WuXi AppTec (603259.SH) reported a revenue of 32.857 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 18.61% [1] - The net profit attributable to shareholders reached 12.076 billion yuan, with a significant year-on-year increase of 84.84% [1] - The net profit excluding non-recurring gains and losses was 9.522 billion yuan, reflecting a year-on-year growth of 42.51% [1] Chemical Business - The chemical business generated revenue of 25.98 billion yuan, marking a year-on-year increase of 29.3% [1] - The small molecule drug discovery ("R") business has successfully synthesized and delivered over 430,000 new compounds for clients in the past twelve months [1] - The company has converted 250 molecules from research to development (R to D) in the first three quarters of 2025 [1] Small Molecule Development and Manufacturing - The small molecule development and manufacturing (D&M) business reported revenue of 14.24 billion yuan, showing a year-on-year growth of 14.1% [2] - A total of 621 new molecules were added to the small molecule D&M pipeline in the first three quarters of 2025, bringing the total to 3,430, which includes 80 commercial projects and 87 clinical phase III projects [2] - The company successfully passed FDA inspections at its Changzhou and Taixing API bases with zero defects in March 2025 [2] TIDES Business - The TIDES business (oligonucleotides and peptides) experienced rapid growth, with revenue reaching 7.84 billion yuan, a year-on-year increase of 121.1% [3] - As of September 2025, TIDES orders on hand grew by 17.1% year-on-year, with the number of clients served increasing by 12% and the number of molecules served rising by 34% [3] - The company completed the capacity expansion for peptides in Taixing ahead of schedule, increasing the total volume of solid-phase synthesis reactors to over 100,000 liters [3]

格隆汇10月26日丨药明康德披露业绩，2025年前三季度实现营收328.6亿元，同比增长18.6%；归属于上 市公司股东的净利润达120.8亿元，同比增长84.8%；第三季度净利润35.15亿元，同比增长53.27%。 ...

Core Viewpoint - WuXi AppTec announced that its wholly-owned subsidiary, Shanghai WuXi, plans to transfer 100% equity stakes in Shanghai Kande Hongyi Medical Clinical Research Co., Ltd. and Shanghai WuXi Jinshi Pharmaceutical Technology Co., Ltd. to Shanghai Shihe Rong Enterprise Management Consulting Co., Ltd. and Shanghai Shihe Mu Enterprise Management Consulting Co., Ltd. for a consideration of RMB 2.8 billion [1] Group 1 - The transaction involves the transfer of two companies under WuXi AppTec's portfolio [1] - The total consideration for the equity transfer is set at RMB 2.8 billion [1]

无锡药明康德新药开发股份有限公司 2025 年第三季度报告 无锡药明康德新药开发股份有限公司 2025 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会及董事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人 Ge Li（李革）、主管会计工作负责人施明及会计机构负责人（会计主管人员）孙瑾保 证季度报告中财务信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 释义 | 常用词语释义 | | | | --- | --- | --- | | 公司、本公司 | 指 | 无锡药明康德新药开发股份有限公司 | | 报告期、本报告期 | 指 | 2025年7月1日至2025年9月30日 | | 报告期末、本报告期末 | 指 | 2025 年 9 月 30 日 | | 股份 | 指 | 本公司股本中每股面值人民币 1.00 元的普通股，包括 A 股及 H | | | | 股 | | 元、万元、亿元 | 指 | ...

证券代码：603259 证券简称：药明康德 公告编号：临 2025-069 无锡药明康德新药开发股份有限公司 关于出售资产的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 交易简要内容： 无锡药明康德新药开发股份有限公司（以下简称"本公司"或"公司"）全 资子公司上海药明康德新药开发有限公司（以下简称"上海药明"或"转让方"） 拟以人民币 28 亿元（为基准股权转让价款，最终股权转让价款（定义见下，下 同）将基于交易协议的相关约定进行调整）的对价向上海世和融企业管理咨询有 限公司（以下简称"受让方 1"）及上海世和慕企业管理咨询有限公司（以下简称 "受让方 2"，与受让方 1 以下合称为"受让方"或"交易对方"）转让其所持有 的上海康德弘翼医学临床研究有限公司（以下简称"康德弘翼"或"目标公司 1"） 和上海药明津石医药科技有限公司（以下简称"津石医药"或"目标公司 2"，与 目标公司 1 以下合称"目标公司"）100%股权（以下简称"本次交易"）。本次 交易项下转让方向受让方出售其所持目标公司 1 和目 ...

药明康德10月26日公告，2025年第三季度实现营业收入120.57亿元，同比增长15.26%；归属于上市公司 股东的净利润35.15亿元，同比增长53.27%；基本每股收益1.24元。 前三季度实现营业收入328.57亿 元，同比增长18.61%；归属于上市公司股东的净利润120.76亿元，同比增长84.84%；基本每股收益4.25 元。 ...

药明康德：全资子公司上海药明拟以人民币28亿元的对价向上海世和融企业管理咨询有限公司及上海世 和慕企业管理咨询有限公司转让其所持有的上海康德弘翼医学临床研究有限公司和上海药明津石医药科 技有限公司100%股权。 ...

Core Viewpoint - WuXi AppTec (603259) reported strong financial performance for Q3 2025, with significant year-on-year growth in both revenue and net profit [1] Financial Performance - The company achieved revenue of 12.057 billion yuan in Q3 2025, representing a year-on-year increase of 15.26% [1] - Net profit for Q3 2025 reached 3.515 billion yuan, showing a substantial year-on-year growth of 53.27% [1] - For the first three quarters of 2025, net profit totaled 12.076 billion yuan, reflecting an impressive year-on-year increase of 84.84% [1] Order Backlog - As of the end of September 2025, the company's backlog of orders for ongoing operations stood at 59.88 billion yuan, which is a year-on-year growth of 41.2% [1]

Investment Rating - The report maintains a positive outlook on the pharmaceutical sector, indicating an "Overweight" rating for the industry, suggesting it is expected to outperform the overall market [32]. Core Insights - The report highlights that the Shenwan Pharmaceutical and Biological Index increased by 0.6% this week, while the Shanghai Composite Index rose by 2.9% and the Wind All A (excluding financials and petrochemicals) increased by 3.7% [4][6]. - The pharmaceutical sector's overall valuation stands at 30.4 times earnings, ranking 9th among 31 Shenwan primary industries [4][8]. - Significant collaborations and clinical trial results were reported, including a $11.4 billion global strategic partnership between Innovent Biologics and Takeda Pharmaceutical, which includes a $1.2 billion upfront payment [5][13]. - Key clinical trial results presented at the 2025 ESMO conference showed promising outcomes for several drugs, indicating advancements in treatment efficacy for various cancers [14][18][19]. Market Performance - The report details the performance of various sub-sectors within the pharmaceutical industry, with notable increases in medical devices (+0.2%), medical consumables (+1.7%), and medical research outsourcing (+5.5%), while traditional Chinese medicine and other biological products saw declines [4][8]. - The report also notes that 99 A-share pharmaceutical companies released their Q3 2025 earnings, with a total revenue of 94.15 billion yuan, reflecting a 1.3% year-on-year increase [20][22]. Key Events - The report mentions that Bairui Tianheng has passed the Hong Kong Stock Exchange hearing and is in the process of listing its H-shares [12]. - The report emphasizes the importance of the 2025 ESMO conference, where several companies presented significant clinical data, enhancing their market visibility and potential investment attractiveness [14][17][18]. Company Recommendations - The report recommends focusing on innovative drug sectors and companies with improving performance in medical devices and upstream sectors, including companies like Hengrui Medicine, Changchun High-tech, and Mindray Medical [5][20].